Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples

Xenobiotica

Volumn 28, Issue 5, 1998, Pages 493-506

  Boobis, A R ^a   McKillop, D ^b   Robinson, D T ^b,c   Adams, D A ^a   McCormick, D J ^d  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c Sanofi Winthrop   (United Kingdom)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; LIVER ENZYME;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER MICROSOME; RADIOCHEMISTRY; SPECTROFLUOROMETRY; ULTRAVIOLET RADIATION;

EID: 0031810018     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982598239416     Document Type: Article

References (49)

1. BALLS, M. and FENTEM, J. H., 1997, Progress toward the validation of alternative tests. ATLA-Alternatives to Laboratory Animal, 25, 33-43.
2. BERTHOU, F., RATANASAVANH, D., RICHE, C., PICART, D., VOIRIN, T. and GUILLOUZO, A., 1989, Comparison of caffeine metabolism by slices, microsomes and hepatocyte cultures from adult human liver. Xenobiotica, 19, 401-417.
3. BOOBIS, A. R., BRODIE, M. J., KAHN, G. C., FLETCHER, D. R., SAUNDERS, J. H. AND DAVIES, D. S., 1981, Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. British Journal of Clinical Pharmacology, 9, 11-19.
4. BROLY, F., LIBERSA, C. and LHERMITTE, M., 1990, Mexiletine metabolism in vitro by human liver. Drug Metabolism and Disposition, 18, 362-368.
5. BROSEN, K., ZEUGIN, T. and MEYER, U. S., 1991, Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clinical Pharmacology and Therapeutics, 49, 609-617.
6. COMBALBERT, J., FABRE, I., FABRE, G., DALET, I., DERANCOURT, J., CANO, J. P. and MAUREL, P., 1989, Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P45011IA gene subfamily. Drug Metabolism and Disposition, 17, 197-207.
7. COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP), EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS: HUMAN MEDICINES EVALUATION UNIT, 1997, Note for guidance on the investigation of drug interactions (in press).
8. EBNER, T., MEESE, C. O. and EICHELBAUM, M., 1995. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans. Molecular Pharmacology 48, 1078-1086.
9. ELLIS, S. W., CHING, M. S., WATSON, P. F., HENDERSON, C. J., SIMULA, A. P., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1992, Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochemical Pharmacology, 44, 617-620.
10. EUGSTER, H. P. and SENGSTAG, C., 1993, Saccharomyces cerevisiae: an alternative source for human microsomal liver enzymes and its use in drug interaction studies. Toxicology, 82, 61-73.
11. FORRESTER, L. M., HENDERSON, C. J., GLANCEY, M. J., BACK, D. J., PARK, B. K., BALL, S. E., KITTERINGHAM, N. R., MCLAREN, A. W., MILES, J. S., SKETT, P. and WOLF, C. R. 1992, Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 281, 359-368.
12. GHOSAL, A., SATOH, H., THOMAS, P. E., BUSH, E. and MOORE, D., 1996, Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition, 24, 940-947.
13. GILLAM, E. M. and REILLY, P. E., 1988, Phenacetin O-deethylation by human liver microsomes: kinetics and popranolol inhibition. Xenobiotica, 18, 95-104.
14. GORSKI, J. C., HALL, S. D., JONES, D. R., VANDENBRANDEN, M. and WRIGHTON, S. A., 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology, 47, 1643-1653.
15. GRANT, D M., CAMPBELL, M. E., TANG, B. K. and KALOW, W., 1987, Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies, Biochemical Pharmacology, 36, 1251-1260.
16. GUENGERICH, F. P., BRIAN, W. R., IWASAKI, M., SARI, M. A., BAARNHIELM, C. and BERNTSSON, P., 1991, Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450IIIA4. Journal of Medicinal Chemistry, 34, 1838-1844.
17. HARRELL, A. W., WHEELER, S. M., PENNICK, M., CLARKE, S. E and CHENERY, R. J., 1993, Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metabolism and Disposition, 21, 18-23.
18. HARRIS, J. W., RAHMAN, A., KIM, B. R., GUENGERICH, F. P. and COLLINS, J. M., 1994, Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Research, 54, 4026-4035.
19. IMAOKA, S., ENOMOTO, K., ODA, Y., ASADA, A., FUJIMORI, M., SHIMADA, T., FUJITA, S., GUENGERICH, F. P. and FUNAE, Y., 1990, Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. Journal of Pharmacology and Experimental Therapeutics, 255, 1385-1391.
20. INABA, T., TAIT, A., NAKANO, M., MAHON, W. A. and KALOW, W., 1988, Metabolism of diazepam in vitro by human liver. Independent variability of N-demethylation and C3-hydroxylation. Drug Metabolism and Disposition, 16, 605-608.
21. KAMINSKY, L. S. and ZHANG, Z. Y., 1997, Human P450 metabolism of warfarin. Pharmacology and Therapeutics, 73, 67-74.
22. KATO, R. and YAMAZOE, Y., 1994, The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics, 4, 359-362.
23. KRONBACH, T., 1991, Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Methods in Enzymology, 206, 509-517.
24. LING, K. H., LEESON, G. A., BURMASTER, S. D., HOOK, R. H., REITH, M. K. and CHENG, L. K., 1995, Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metabolism and Disposition, 23, 631-636.
25. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurements with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
26. LUCAS, D., MENEZ, J. F. and BERTHOU, F., 1996, Chlorzoxazone: an in vitro and in vivo substrate probe for liver CYP2E1. Methods in Enzymology, 272, 115-123.
27. MINERS, J. O., SMITH, K. J., ROBSON, R. A., MCMANUS, M. E., VERONESE, M. E. and BIRKETT, D. J., 1988, Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochemical Pharmacology, 37, 1137-1144.
28. ONO, S., HATANAKA, T., HOTTA, H., TSUTSUI, M., SATOH, T. and GONZALEZ, F. J., 1995, Chlorzoxazone is metabolized by human CYP 1A2 as well as by human CYP2E1. Pharmacogenetics, 5, 143-150.
29. PEARCE, R. E., MCINTYRE, C. J., MADAN, A., SANZGIRI, U., DRAPER, A. J., BULLOCK, P. L., COOK, D. C., BURTON, L. A., LATHAM, J., NEVINS, C. and PARKINSON, A., 1996, Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Archives of Biochemistry and Biophysics, 331, 145-169.
30. PECK, C. R., TEMPLE, R. and COLLINS, J. M., 1993, Understanding consequences of concurrent therapies. Journal of the American Medical Association, 269, 1550-1552.
31. RENAUD, J. P., CULLIN, C., POMPON, D., BEAUNE, P. and MANSUY, D., 1990, Expression of human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic enzyme. European Journal of Biochemistry, 194, 889-896.
32. RODRIGUES, A. D., 1994, Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochemical Pharmacology, 48, 2147-2156.
33. RUTTEN, A. A., FALKE, H. E., CATSBURG, J. F., TOPP, R., BLAAUBOER, B. J., VAN HOLSTEIJN, I., DOOM, L. and VAN LEEUWEN, F. X., 1987, Interlaboratory comparison of total cytochrome P-450 and protein determinations in rat liver microsomes. Reinvestigation of assay conditions. Archives of Toxicology, 61, 27-33.
34. RUTTEN, A. A., FALKE, H. E., CATSBURG, J. F., WORTELBOER, H. M., BLAAUBOER, B. J., DOOM, L., VAN LEEUWEN, F. X., THEELEN, R. and RIETJENS, I. M., 1992, Interlaboratory comparison of microsomal ethoxyresorufin and pentoxyresorufin O-dealkylation determinations: standardization of assay conditions. Archives of Toxicology, 66, 237-244.
35. SESARDIC, D., BOOBIS, A. R., EDWARDS, R. J. and DAVIES, D. S., 1988, A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology, 26, 363-372.
36. SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. and DAVIES, D. S., 1990a, Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology, 29, 651-663.
37. SESARDIC, D., PASANEN, M., PELKONEN, O. and BOOBIS, A. R., 1990b, Differential expression and regulation of members of the cytochrome P450IA gene subfamily in human tissues. Carcinogenesis, 11, 1183-1188.
38. SHARER, J. E., SHIPLEY, L. A., VANDENBRANDEN, M. R., BINKLEY, S. N. and WRIGHTON, S. A., 1995, Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition, 23, 1231-1241.
39. SHIMADA, S., MIMURA, M., INOUE, K., NAKAMARA, S., ODA, H., OHMORI, S. and YAMAZAKI, H., 1997, Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys and humans. Archives of Toxicology, 71, 401-108.
40. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
41. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. and MINERS, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401-407.
42. TASSANEEYAKUL, W., MOHAMED, Z., BIRKETT, D. J., MCMANUS, M. E., VERONESE, M. E., TUKEY, R. H., QUATTROCHI, L. C., GONZALEZ, F. J. and MINERS, J. O., 1992, Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics, 2, 173-183.
43. TEMPLE, R. J., 1996, The clinical pharmacologist in drug regulation: the US perspective. British Journal of Clinical Pharmacology, 42, 73-79.
44. TRANSON, C., LECOEUR, S., LEEMANN, T., BEAUNE, P. and DAYER, P., 1996, Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. European Journal of Clinical Pharmacology, 51, 79-85.
45. US FOOD AND DRUG ADMINISTRATION, CENTER FOR DRUG EVALUATION AND RESEARCH, 1997, Guidance for industry. Drug metabolism/drug interaction studies in the drug development process: studies in vitro.
46. VERONESE, M. E., DOECKE, C. J., MACKENZIE, P. I., MCMANUS, M. E., MINERS, J. O., REES, D. L., GASSER, R., MEYER, U. A. and BIRKETT, D. J., 1993, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal, 289, 533-538.
47. WATKINS, P. B., WRIGHTON, S. A., MAUREL, P., SCHUETZ, E. G., MENDEZ-PICON, G., PARKER, G. A. and GUZELIAN, P. S., 1985, Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences, USA, 82, 6310-6314.
48. WRIGHTON, S. A., VANDENBRANDEN, M., STEVENS, J. C., SHIPLEY, L. A., RING, B. J., RETTIE, A. E. and CASHMAN, J. R., 1993, In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metabolism Reviews, 25, 453-484.
49. YAMAZAKI, H., INOUE, K., TURVY, C. G., GUENGERICH, F. P. and SHIMADA, T., 1997, Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metabolism and Disposition, 25, 168-174.